Evidence map›Paper›PMID 25613718›Full record

ArticleVaccine2015

Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.

Paweł M Bęczkowski, Matthew Harris, Navapon Techakriengkrai, Julia A Beatty, Brian J Willett, Margaret J Hosie

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. 2020 AAFP Feline Retrovirus Testing and Management Guidelines.Journal of feline medicine and surgery · 2020
    Guideline
  2. WSAVA Guidelines for the vaccination of dogs and cats.The Journal of small animal practice · 2016
    Guideline
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Paweł M BęczkowskiCentre for Virus Research, University of Glasgow, Glasgow, United Kingdom; Small Animal Hospital, University of Glasgow, Glasgow, United Kingdom. Electronic address: pawel.beczkowski@glasgow.ac.uk.
Matthew HarrisCentre for Virus Research, University of Glasgow, Glasgow, United Kingdom. Electronic address: m.harris.2@research.gla.ac.uk.
Navapon TechakriengkraiCentre for Virus Research, University of Glasgow, Glasgow, United Kingdom. Electronic address: n.techakriengkrai.1@research.gla.ac.uk.
Julia A BeattyValentine Charlton Cat Centre, University of Sydney, Sydney, NSW, Australia. Electronic address: julia.beatty@sydney.edu.au.
Brian J WillettCentre for Virus Research, University of Glasgow, Glasgow, United Kingdom. Electronic address: brian.willett@glasgow.ac.uk.
Margaret J HosieCentre for Virus Research, University of Glasgow, Glasgow, United Kingdom. Electronic address: margaret.hosie@glasgow.ac.uk.
MRC University of Glasgow Centre for Virus Research · GBUniversity of Sydney · AU

Funding

Biotechnology and Biological Sciences Research Council BB/D008425/1Medical Research Council G0300387Wellcome TrustWellcome Trust 10361Wellcome Trust 5255
6 · The paper itself

Abstract

Across human and veterinary medicine, vaccines against only two retroviral infections have been brought to market successfully, the vaccines against feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV). FeLV vaccines have been a global success story, reducing virus prevalence in countries where uptake is high. In contrast, the more recent FIV vaccine was introduced in 2002 and the degree of protection afforded in the field remains to be established. However, given the similarities between FIV and HIV, field studies of FIV vaccine efficacy are likely to advise and inform the development of future approaches to HIV vaccination. Here we assessed the neutralising antibody response induced by FIV vaccination against a panel of FIV isolates, by testing blood samples collected from client-owned vaccinated Australian cats. We examined the molecular and phenotypic properties of 24 envs isolated from one vaccinated cat that we speculated might have become infected following natural exposure to FIV. Cats vaccinated against FIV did not display broadly neutralising antibodies, suggesting that protection may not extend to some virulent recombinant strains of FIV circulating in Australia.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCatsFeline Acquired Immunodeficiency SyndromeFemaleHumansImmunodeficiency Virus, FelineMalePhylogenyProvirusesReceptors, VirusViral Envelope ProteinsViral InterferenceViral VaccinesAntibodies, NeutralizingAntibodies, ViralReceptors, VirusViral Envelope ProteinsViral VaccinesFIV vaccineNeutralising antibodiesVaccine induced protection

Identifiers

PMID25613718
PMCPMC4327927
OpenAlexW1980185182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.